Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

AvenCell Therapeutics, Inc. was recently launched by Blackstone Life Sciences, Cellex Cell Professionals, and Intellia Therapeutics and incorporated the clinical-stage biopharmaceutical company GEMoaB GmbH, now named AvenCell Europe GmbH. With $250 million in committed capital from Blackstone as its sole founding investor, AvenCell brings together switchable universal T cell technology developed by the former Cellex subsi...
AvenCell Therapeutics, Inc. was recently launched by Blackstone Life Sciences, Cellex Cell Professionals, and Intellia Therapeutics and incorporated the clinical-stage biopharmaceutical company GEMoaB GmbH, now named AvenCell Europe GmbH. With $250 million in committed capital from Blackstone as its sole founding investor, AvenCell brings together switchable universal T cell technology developed by the former Cellex subsidiary GEMoaB GmbH.

List your booth number for exhibitions, ask us